United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GlaxoSmithKline

The CDC panel's recommendation moves the U.S. closer to making the respiratory syncytial virus shots from Pfizer and GSK available to seniors.

CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults over 60

Following FDA's label-expansion approval, Pfizer's (PFE) Talzenna is the first PARP inhibitor approved in combination with existing standard of care for treating HRR gene-mutated mCRPC.

FDA Expands Pfizer's (PFE) Talzenna Label in Prostate Cancer

Conagra Brands

Altria

Philip Morris

Walmart

Exxon Mobil

While there are many good quality undervalued stocks, it's clear that some are best in class. I decided to share our picks with the SA community. Here are two of our favorite dividend stocks in the current environment.

Buy Right, Sell Right: 2 Top Dividend Buys From Our Top 10 List

JPMorgan Chase & Co

Starbucks

This article discusses three high-quality blue-chip dividend stocks that can provide investors with monthly dividend income when staggered. These stocks are currently trading at reasonable valuations and have strong financials, making them attractive options for investors seeking regular income. All three stocks have shown the ability to generate strong free cash flow, which has led to rising dividend payouts.

Earn A Dividend Check Every Month With These 3 Stocks

Pfizer will present the RSV vaccine results to a CDC advisory committee, which will decide when and how often the shot should be administered in the U.S.

Pfizer RSV vaccine for older adults is only slightly less effective after 18 months

A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday will vote on whether to recommend the use of recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.

US CDC advisers weigh use of GSK, Pfizer RSV vaccines in older adults

NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide), for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). This approval is based on the statistically significant and clinically meaningful radiographic progression.

Pfizer's TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval

AbbVie

Home Depot

Infosys

Occidental Petroleum

PayPal

Thermo Fisher Scientific

While the smaller-capitalization trades tend to attract the most speculative attention, for reliable upside prospects, investors may want to consider blue-chip stocks to buy. To better understand the motivation behind targeting these stalwarts, a baseball analogy may be helpful.

Ready for a Rebound: 7 Blue-Chips Set to Regain Their Market Mojo

DiCE Molecules Holding LLC

Biotech stocks to watch in the stock market now.

2 Biotech Stocks For Your June 2023 Watchlist

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 1, 2023. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2023 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Infor.

Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts

Moderna

Novavax

The FDA's strain selection puts Pfizer, Moderna and Novavax on track to deliver updated coronavirus shots in time for the fall.

Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head start

CRISPR Therapeutics

iBio

Even the most conservative investor hopes to find that one stock that can make them millions. That's why they look at the biotech sector.

3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever

Apple

Broadcom

Caterpillar

Chevron

Coca-Cola

There are several reasons to seek out high-cash-flow stocks. In the simplest terms, companies that generate strong cash flow can pay – and increase – dividends, develop new products and buy back shares among other things.

Unlock the Potential of These 7 Cash-Flow Machines

Deutsche Post AG

Kraft Heinz

Companies with a high Dividend Yield can help you enormously to build an extra income without the need to sell stocks from your portfolio. I have selected three companies that provide you with a relatively high Dividend Yield and that I consider to be undervalued. In addition to that, the three selected picks can help you reduce portfolio volatility and therefore reduce its risk level, thus limiting the downside risk.

3 High Dividend Yield Companies With A Low Valuation

Bristol-Myers

Teva Pharmaceutical

Bristol Myers Squibb stock is too cheap to ignore. Pfizer has more good news on the way than meets the eye.

3 Bargain Stocks to Buy on the Dip

BioNTech SE

The U.S. Food and Drug Administration (FDA) said on Friday it has advised manufacturers that are updating their COVID-19 vaccines to develop monovalent shots to target the XBB.1.5 subvariant.

US FDA advises COVID vaccine makers to develop shots aimed at XBB.1.5 variant

The FDA's decision is a win for vaccine makers Pfizer, Moderna and Novavax, which have all been developing versions of their Covid shots to target XBB.1.5.

FDA recommends that updated Covid shots target omicron subvariant XBB.1.5 this fall

An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.

FDA Panel Endorses Updating COVID Jab to Target XBB Strain

Today's vaccines still contain the original coronavirus strain, the one that started the pandemic — even though that was long ago supplanted by mutated versions as the virus rapidly evolves.

FDA advisers endorse updating COVID vaccines to target latest omicron strain

Teladoc

Teladoc's new strategy is starting to bear fruit. There's more to like about Pfizer than many investors might realize.

2 Stocks Down 11% and 20% to Buy Right Now

AllianceBernstein Hld

Arbor Realty Trust

American Tower

Ares Capital

Alexandria Real Estate Equities

BHP Billiton

British American Tobacco

March-April 2022, UBS, Kiplinger, and Barron's analysts/reporters listed five sets of stocks sorted as “Inflation Busters.” Those five-articles revealed 48 equities, with 43 paying-dividends. This over one-year-old list continues to beat-back new-strains-of-inflation.

11 Buyable Inflation-Busting June Dividend Stocks

News for Pfizer Stock (PFE)